Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868628 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2 study of Multiple System Atrophy, sponsored by Tiziana Life Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06868628 is a Phase 2 study of Multiple System Atrophy that is actively recruiting participants, run by Tiziana Life Sciences. The registered enrollment target is 5 participants, below the 268-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06868628, a Phase 2 study of Multiple System Atrophy, is actively recruiting participants, sponsored by Tiziana Life Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
Conditions Studied
Interventions
- DRUG Foralumab Nasal
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868628
The ClinicalTrials.gov registry entry for NCT06868628 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (98% lower). The listed sponsor is Tiziana Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Foralumab Nasal is the first listed.
NCT06868628 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06868628 about?
NCT06868628 is a clinical study titled "A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)". A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
What is the current status of trial NCT06868628?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2025-05-19. Estimated completion is 2027-04-01.
What conditions does trial NCT06868628 study?
This clinical trial studies the following conditions: Multiple System Atrophy.
What interventions are being tested in trial NCT06868628?
The interventions under investigation include: Foralumab Nasal (DRUG).
Who is sponsoring clinical trial NCT06868628?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868628 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
RECRUITING · Phase 2
-
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
RECRUITING · Phase 2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.